6.
Lockwood T
. Lysosomal metal, redox and proton cycles influencing the CysHis cathepsin reaction. Metallomics. 2013; 5(2):110-24.
DOI: 10.1039/c2mt20156a.
View
7.
Andrault P, Panwar P, Mackenzie N, Bromme D
. Elastolytic activity of cysteine cathepsins K, S, and V promotes vascular calcification. Sci Rep. 2019; 9(1):9682.
PMC: 6609650.
DOI: 10.1038/s41598-019-45918-1.
View
8.
Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M
. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022; 375(6586):1254-1261.
PMC: 9273333.
DOI: 10.1126/science.abf0529.
View
9.
Andrault P, Panwar P, Bromme D
. Characterization of cathepsin S exosites that govern its elastolytic activity. Biochem J. 2019; 477(1):227-242.
DOI: 10.1042/BCJ20190847.
View
10.
Gorican T, Ciber L, Petek N, Svete J, Novinec M
. Synthesis and kinetic characterization of hyperbolic inhibitors of human cathepsins K and S based on a succinimide scaffold. Bioorg Chem. 2021; 115:105213.
DOI: 10.1016/j.bioorg.2021.105213.
View
11.
Riese R, Wolf P, Bromme D, Natkin L, Villadangos J, Ploegh H
. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996; 4(4):357-66.
DOI: 10.1016/s1074-7613(00)80249-6.
View
12.
Brown R, Nath S, Lora A, Samaha G, Elgamal Z, Kaiser R
. Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics. Respir Res. 2020; 21(1):111.
PMC: 7216426.
DOI: 10.1186/s12931-020-01381-5.
View
13.
McClung M, ODonoghue M, Papapoulos S, Bone H, Langdahl B, Saag K
. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019; 7(12):899-911.
DOI: 10.1016/S2213-8587(19)30346-8.
View
14.
De Marzi L, Monaco A, de Lapuente J, Ramos D, Borras M, Di Gioacchino M
. Cytotoxicity and genotoxicity of ceria nanoparticles on different cell lines in vitro. Int J Mol Sci. 2013; 14(2):3065-77.
PMC: 3588031.
DOI: 10.3390/ijms14023065.
View
15.
Gauthier J, Chauret N, Cromlish W, Desmarais S, Duong L, Falgueyret J
. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008; 18(3):923-8.
DOI: 10.1016/j.bmcl.2007.12.047.
View
16.
Schenker P, Baici A
. Paradoxical interactions between modifiers and elastase-2. FEBS J. 2010; 277(11):2486-95.
DOI: 10.1111/j.1742-4658.2010.07663.x.
View
17.
Tato M, Kumar S, Liu Y, Mulay S, Moll S, Popper B
. Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. Sci Rep. 2017; 7(1):2775.
PMC: 5459853.
DOI: 10.1038/s41598-017-01894-y.
View
18.
Conaghan P, Bowes M, Kingsbury S, Brett A, Guillard G, Rizoska B
. Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial. Ann Intern Med. 2019; 172(2):86-95.
DOI: 10.7326/M19-0675.
View
19.
Cardenas C, Ayers P
. How reliable is the hard-soft acid-base principle? An assessment from numerical simulations of electron transfer energies. Phys Chem Chem Phys. 2013; 15(33):13959-68.
DOI: 10.1039/c3cp51134k.
View
20.
Williams D, Basnet K, Grant K
. Tuning Cerium(IV)-Assisted Hydrolysis of Phosphatidylcholine Liposomes under Mildly Acidic and Neutral Conditions. Chembiochem. 2015; 16(10):1474-82.
DOI: 10.1002/cbic.201500041.
View